A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs).

Authors: Bahar Laderian, Mengxi Zhou, Lyndon Luk, Susan Elaine Bates, Antonio Tito Fojo, Jaydira Del Rivero

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.10612

Source: Full article

---

Abstract

10612